The MK-7622 is the first-of-its-kind oral positive allosteric modulator of M1 muscarinic receptors, developed by Merck for the treatment of Alzheimer’s disease, with a structure comprising a benzoquinazolinone bearing additional complex substituents at positions 3 and 6. MK-7622 failed to pass Phase II clinical trials for the treatment of Alzheimer's disease (as an adjunctive therapy) and has been withdrawn from production.
Pharmacology Pharmacodynamics MK-7622 acts as a highly selective positive allosteric modulator of the M1 muscarinic receptor; it exhibits the properties of an allosteric agonist and is characterised by a predominant enhancement of beta-arrestin-associated signalling rather than balanced modulation, which is the cause of some of its cholinergic side effects.
Side effects Side effects included behavioural seizures and cognitive impairment.
References